Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 04 Nov 2025, 04:48 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]](https://i.ytimg.com/vi/8Fmx2vFY1Lc/hqdefault.jpg)
AI-generated source summary
The analysis indicates Nuvation Bio Inc. as a Buy Candidate with a score of 3.304 as of November 3rd, 2025. It has demonstrated a gain of 39.73% over the past 11 days, averaging 3.61% daily. The stock is positioned within a robust short-term upward trend, with a potential change of approximately 74.83% over the next three months, and a 12-month forecast projecting a 24.39% change, with a price range between $2.63 and $6.70. On November 3rd, 2025, the stock closed at $5.17, experiencing a 0.96% decrease with a daily fluctuation of 5.49% and a volume of 7 million shares. Its 52-week high was $5.55, while the all-time high was $15.23 on May 26th, 2021. News includes 204 new patients receiving IBTROZI, regulatory approval in Japan, and insider trading activity showing both purchases and sales. However, general ratings indicate a Strong Sell for Return on Equity, Return on Asset, and Dividend Earnings, with a negative P/E ratio of -8.68. Technical signals show short and long-term Moving Averages giving a positive forecast, with a MACD buy signal and a Bollinger Band buy signal from 57 days ago. There is a sell signal from a pivot top found 4 days prior, indicating a 3.72% decline since. The stock exhibits very high weekly volatility at 6.70%. Key resistance is identified at $5.22, with support at $5.15. The consensus earnings estimate for Q3 2025 is -0.17. The analysis concludes with an expectation for Nuvation Bio to open higher by approximately $0.0467, trading at $5.22 on November 4th, suggesting a buying opportunity in the short-term.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
